Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
Study sponsor: Arcutis Biotherapeutics, Inc. · ARQT
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2020-08-18Actual
Enrollment · participants226Actual
Source updated2023-07-03Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.